Evommune

Verified by our team

  • Biotech
Linkedin Twitter Facebook

Evommune is a clinical-stage biotechnology company developing novel therapies for immune-mediated chronic inflammatory diseases, aiming to address root causes rather than just symptoms, with a focus on long-term disease progression and complications.

Evommune Highlights:

  • Evommune annual revenue is $3.8M.
  • Evommune total funding is $153.0M.
  • Evommune headquartered in Palo Alto, California.
  • Evommune number of employees is 49.

    • Overview

    • Website: evommune.com
    • Headquarters: Palo Alto, California
    • Employees: 49
    • Founded: 2020
    • Email: admin@evommune.com
    • Funding: $153.0M
    • Revenue: $3.8M
    • Valuation: n/a

    Contacts

    Kyle Carver

    CFO
    Linkedin
    • Email: ***@evommune.com
    Buy the List to Unlock Contacts

    Similar companies

    Frequently Asked Questions related to Evommune

    Evommune is located in Palo Alto, California.
    Yes, Evommune is a Silicon Valley company.
    Evommune total funding is 153.0M.
    Evommune revenue is 3.8M.
    Evommune’s number of employees is 49.
    Evommune’s CEO name is Kyle Carver.
    Evommune was founded in 2020.
    Evommune’s contact email is admin@evommune.com.

    Follow Silicon Valley Journals

    Awarded by

    corporate vision magazine

    © Copyright 2022-2024 Silicon Valley Journals. All rights reserved.

    Fundings

    Quick links

    Company

    © Copyright SVJ Media Ltd., 71-75 Shelton Street. Covent Garden. London, GB WC2H 9JQ